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Abstract
Background: The characterization and cellular localization of transcription factors like NF-B requires the use of
antibodies for western blots and immunohistochemistry. However, if target protein levels are low and the
antibodies not well characterized, false positive data can result. In studies of NF-B activity in the CNS, antibodies
detecting NF-B proteins have been used to support the finding that NF-B is constitutively active in neurons, and
activity levels are further increased by neurotoxic treatments, glutamate stimulation, or elevated synaptic activity.
The specificity of the antibodies used was analyzed in this study.
Methods: Selectivity and nonselectivity of commonly used commercial and non-commercial p50 and p65
antibodies were demonstrated in western blot assays conducted in tissues from mutant gene knockout mice
lacking the target proteins.
Results: A few antibodies for p50 and p65 each mark a single band at the appropriate molecular weight in gels
containing proteins from wildtype tissue, and this band is absent in proteins from knockout tissues. Several
antibodies mark proteins that are present in knockout tissues, indicating that they are nonspecific. These include
antibodies raised against the peptide sequence containing the nuclear localization signals of p65 (MAB3026;
Chemicon) and p50 (sc-114; Santa Cruz). Some antibodies that recognize target proteins at the correct molecular
weight still fail in western blot analysis because they also mark additional proteins and inconsistently so. We show
that the criterion for validation by use of blocking peptides can still fail the test of specificity, as demonstrated for
several antibodies raised against p65 phosphorylated at serine 276. Finally, even antibodies that show specificity in
western blots produce nonspecific neuronal staining by immunohistochemistry.
Conclusions: We note that many of the findings in the literature about neuronal NF-B are based on data
garnered with antibodies that are not selective for the NF-B subunit proteins p65 and p50. The data urge caution
in interpreting studies of neuronal NF-B activity in the brain.
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Background
NF-B is a transcription factor that is ubiquitously pre-
sent in all cells of the body. It exists as a homo- or het-
ero-dimer comprising typically p50 and p65 (RelA)
subunits, but also combinations of these subunits with
other members of the Rel family, such as p52, c-Rel and
RelB [1]. Activation of NF-B by enzymatic degradation
of the bound inhibitory protein, predominantly IBa,
results in exposure of the nuclear localization signal
(NLS) on p50 and p65, allowing movement of the subu-
nits from the cytoplasm to the nucleus where they bind
to consensus B sequences in the DNA. Characteriza-
tion of this activity is afforded by the use of antibodies
that recognize and mark the proteins in western blots of
cytoplasmic and nuclear protein fractions. Antibodies
are used also in EMSA supershift and immunoprecipita-
tion experiments, both of which are commonly used to
study transcription factor activity. Identification of the
cell types showing activity is achieved by microscopic
localization of the antibody-tagged subunits with immu-
nohistochemistry (IHC) or immunocytochemistry (IC).
In the NF-B/Rel field, numerous commercial and non-
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commercial antibodies have been raised against all the
subunits and also against activated (e.g., phosphorylated)
forms of the molecules.
NF-B function is most studied in the immune system
[2], but it has been shown to be present in the brain, in
both neurons and non-neuronal cells, notably glia [3]. Of
the main techniques for measuring NF-B activity, most
lack the ability to distinguish the cell types activated.
Microscopic techniques that can distinguish cell types
include in situ hybridization histochemistry (ISHH),
which localizes changes in gene transcription levels in
cells, and IHC/IC, which identifies protein locations and
levels in phenotyped cells. After NF-B was identified as
a CNS transcription factor, studies on its localization in
the nervous system blossomed. Many of the studies
painted a complex and contradictory picture of NF-B
function in the CNS. Strikingly, whereas ISHH of IBa
mRNA transcription indicated that NF-B activity was
confined to non-neuronal cells, IHC painted a different
picture, showing neuronal as well as non-neuronal stain-
ing of NF-B subunits in various paradigms and assays.
All of the techniques that rely on antibodies require
antibody specificity to ensure that the assay is truly track-
ing NF-B proteins. An antibody is specific if it recog-
nizes and binds to the epitope in the target protein and
to no other molecular or nonspecific entities. Validation
of antibody specificity for IHC is typically done by a set
of control experiments that involve omission of the pri-
mary antibody and co-incubation of the preparation with
an excess amount of the peptide used for immunization.
Another important test of specificity is the demonstration
in western blot that the antibody binds to a single protein
that runs in the gel at a molecular weight that is expected
of the target molecule. The most stringent of control
tests is the demonstration that the binding or staining of
the antibody is absent in tissues or cells from a genetic
mutant animal that has been engineered to lack that pro-
tein, i.e., a knockout (KO) mouse. Surprisingly, there are
ample cases of antibodies that “pass” all the control tests
except the last one. Thus, this study used the resource of
tissue from p50 KO and p65 KO mice to test a number
of widely used NF-B antibodies. Only a few antibodies
passed all of the tests, and several widely used antibodies
failed. The most significant failures were antibodies
raised against the region containing the NLS of both p65
and p50. A review of the literature on NF-B in brain
reveals that most of the claims of constitutive or induced
NF-B activity in neurons are based on results obtained
with antibodies that failed the rigorous specificity test.
Methods
Animals
C57BL/6 mice were obtained from The Jackson Labora-
tories. The rela-/-/tnfr1-/- (p65 KO) mice were a gift of
Mollie Meffert [4,5], and nfkb1-/- (p50 KO) mice were a
gift of Christopher Hunter [6,7]. In both mice, the gene
deletion results in complete elimination of the entire
protein. The p50 KO mouse also lacks p105, the longer
bioactive nfkb1 gene product and precursor to p50, but
for clarity in the text, only the p50 KO is noted in the
designation. The p65 KO mouse has additional deletion
of the Type 1 TNF receptor, which permits survival of
the mouse into adolescence [8], and for clarity, the p65/
TNFR1 double KO is called the p65 KO. All animal pro-
cedures were approved by the Animal Care and Use
Committee of the Intramural Research Program, NIMH.
Antibodies used
Antibodies directed against p65 and p50 were obtained
from commercial sources (Santa Cruz Biotechnology,
Santa Cruz, CA; Chemicon and Upstate (Millipore), Bill-
erica, MA; Calbiochem, St. Louis MO; Cell Signaling,
Beverly, MA; Abcam, Cambridge, MA; Epitomics, Bur-
lingame, CA) or from the NIH, including a p65 antibody
that was a gift of Ulrich Siebenlist, National Institute of
Allergy and Infectious Diseases, NIH, and antibodies
deposited by Dr. Nancy Rice, National Cancer Institute,
NIH, into the repository of the Biological Resources
Branch, NCI, Frederick, MD (http://web.ncifcrf.gov/
research/brb/reagents/AntiseraReagent.aspx). The list of
antibodies tested for the study is provided in Table 1.
Primary cell culture
Neurons
Mouse neurons were cultured from 16-day embryonic
C57BL/6 mouse brains as described previously [9]. Hippo-
campi or cortices were dissected out in cold Hanks
balanced salt solution (HBSS) after careful removal of
meninges and were trypsinized (final 0.05% concentration)
for 15 min at 37°C. The digested tissues were washed
twice with Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen, Carlsbad, CA) containing 10% fetal bovine
serum (FBS) (Invitrogen) and triturated. Large cellular
debris was removed using a 40-μm nylon strainer, and
smaller cellular debris was removed by centrifuging at 200
× g for 5 minutes. The pellet was resuspended in Neuro-
basal medium supplemented with B27 (1X), Glutamax (2
mM), penicillin (100 U/ml), and streptomycin (100 mg/
ml) (all from Invitrogen) and seeded onto poly d-lysine
coated coverslips at a density of 0.10 × 106 cells/well for
immunocytochemistry and in 6-well plates at 2 × 106
cells/well for western blots. Neurons were maintained at
37°C in the presence of 5% CO2/95% O2. After four days
in culture, the medium was changed to fresh supplemen-
ted Neurobasal medium in some experiments containing
also cytosine arabinoside (araC) (10 mM) and 2-deoxycyti-
dine (100 mM) (Sigma) to inhibit astrocyte growth. After
10 days in culture, the cells were subjected to the various
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experimental conditions and processed for either immu-
nostaining or immunoblotting.
Mixed brain cells
Mouse brain cells comprising astrocytes, microglia,
fibroblasts, and some neurons were cultured from 16-
day embryos. Subcortical pieces were dissected out in
cold HBSS, homogenized, pelleted, resuspended, and
plated for 10 days as above except the medium con-
tained only DMEM with 10% FBS, penicillin (100 U/ml),
and streptomycin (100 mg/ml).




Anti p65 antibodies (C-terminus-directed listed first)
sc-372G/R Goat or rabbit polyclonal to aa 531-550 (C-20) Santa Cruz
NIH p65
(7057)
Rabbit polyclonal to aa 538-550 NIH-Siebenlist
PC137 Rabbit polyclonal to C-term (within the last 60 aas) Same as Chemicon (AB 1604), Rockland (100-4165), and Upstate
(now Millipore)
Calbiochem
1546 Rabbit monoclonal to C-terminus Epitomics
2A12A7 Mouse monoclonal to aa 375-550 Invitrogen
3034 Rabbit polyclonal to region around Ser276 Cell Signaling
4764 Rabbit monoclonal to N-terminus Cell Signaling
sc-109 Rabbit polyclonal to N-terminus Santa Cruz
sc-8008 Monoclonal to N-terminal aa 1-286 Santa Cruz
“Activated” p65 antibodies
MAB3026 Clone 12H11; monoclonal to region of NLS (formerly Boehringer and Roche #1697838; originally Kaltschmidts’ a-
p65M)
Chemicon
3037 Rabbit polyclonal to phospho-Ser276-p65 Cell Signaling
2615 Rabbit polyclonal to phospho-Ser276-p65 Abcam
Nancy Rice (NCI, Frederick, MD repository) rabbit polyclonal p65 antibodies
1226-TB3 C terminus NCI
repository
1774 TB11 downstream of NLS NCI
repository
1207-TB4 N terminus NCI
repository
33-TB4 downstream of NLS (mouse sequence) NCI
repository
Anti p50 antibodies
ab7971 Rabbit polyclonal to aa 330-433 Abcam
sc-8414 Monoclonal to aa 120-239 Santa Cruz
06-886 Rabbit polyclonal to aa 1-12 Upstate
3035 Rabbit polyclonal to N-terminal Cell Signaling
1559 Rabbit monoclonal between aa 340-370 Epitomics
“Activated” p50 antibody
sc-114 Rabbit polyclonal to region of NLS (at 357-365) Santa Cruz
Nancy Rice (NCI, Frederick, MD repository) rabbit polyclonal p50 antibodies
1263-TB7 N terminus of mouse p50 NCI
repository




Manufacturers’ information about location of amino acid (aa) sequences of the human protein that the antibody was raised against.
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Kainic acid (KA) treatment of animals
Mice were maintained in the animal colony under stan-
dard housing and ad lib feeding conditions. Kainic acid
(Tocris, Ellisville, MO) was dissolved in sterile water
immediately before use. From a stock solution of 0.3
mg/ml, 1.0 μl was slowly infused with a Hamilton syr-
inge stereotaxically lowered to the coordinates A-P +1.5,
M-L -2.4, D-V 3+3.8 with respect to the interaural line
for intrahippocampal injections. Injections were made i.
p. at 30 mg/kg.
Preparation of tissue extracts
Samples from whole brain, liver, or spleen or from cul-
tured cells were homogenized on ice (with sonication
for tissues) in T-PER reagent (Tissue Protein Extraction
Reagent, Pierce Biotechnology, Rockford, IL). Protein
concentration of these whole cell extracts was deter-
mined using the BioRad Protein Assay Reagent (BioRad,
Hercules, CA) according to the manufacturer’s instruc-
tions. Cytosolic and nuclear extracts of cortical neurons
were prepared using the NE-PER kit (Pierce) according
to the manufacturer’s instructions. Both the T-PER
reagent and the buffers in the NE-PER kit were supple-
mented with both a protease inhibitor cocktail (HALT,
Pierce Biotechnology, Rockford, IL) and a phosphatase
inhibitor cocktail (Phosphatase Inhibitor Cocktail 1,
Sigma Life Science, St. Louis, MO).
Western blots
Protein samples of either tissue extracts or individual
cytosolic or nuclear extracts were loaded in equal
amounts into individual wells of a 10% polyacrylamide-
SDS gel and the proteins resolved using MOPS-SDS
buffer. Proteins were transferred to a PVDF membrane
(Millipore-Immobilon-P, Bedford, MA) for 2 h at room
temperature, and then the nonspecific sites were
blocked with 5% Dried milk in Tris-Buffered Saline con-
taining 0.05% Tween-20 (TBST buffer) with gentle
washing for 2 h at room temperature. The membranes
were incubated overnight at 4°C in a fresh solution of
5% dried milk-TBST containing antiserum for p50 or
p65 at optimized dilutions for each antibody. After the
overnight incubation, membranes were washed three
times with TBST (10 min each) and re-incubated with a
goat anti-rabbit IgG-HRP secondary antiserum (Pro-
mega Corporation, Madison, WI) diluted in 5% dried
milk-TBST for 4 h at room temperature. The mem-
branes were washed three times with TBST (10 min
each), reacted with the West Duro Chemiluminescent
substrate (Pierce) and exposed to X-ray film to visualize
protein present in the samples. Approximate molecular
weights of the target proteins were determined by com-
parison to a BenchMark prestained protein ladder
(Invitrogen).
Immunocytochemistry (IC)
Neurons were fixed on coverslips in 4% PBS-paraformal-
dehyde for 30 min at room temperature, washed with
PBS and then permeabilized with 0.1% Triton X-100
(Sigma) in PBS for 15 min at room temperature. The
cells were blocked with PBS-0.1% Triton containing 5%
Normal Goat Serum (NGS) for one hour at room tem-
perature and incubated overnight at 4°C with the appro-
priate primary antiserum diluted in PBS-0.1% Triton-5%
NGS. Antiserum tested was sc-372G (Santa Cruz) at
1:700 dilution. After washing with PBS-0.1% Triton, the
cells were incubated for 2 h at room temperature with
the anti-goat biotinylated secondary antibody followed
by avidin, biotinylated enzyme, and diaminobenzidine
using the Vectastain Elite ABC kit (Vector Labs, Burlin-
game, CA) for brown color reaction. Coverslips were
inverted and fixed to slides with Permount for later
examination under a microscope (Leica DMR) and CCD
camera (CoolSnap cf, Photometrics, Tucson, AZ).
Immunohistochemistry (IHC)
Mice were deeply anesthetized (pentobarbital plus
chloral hydrate) and transcardially perfused with saline
followed by freshly prepared phosphate buffered 4% par-
aformaldehyde. Brains were removed and stored in the
same fixative followed by transfer to a 20% sucrose solu-
tion. Microtome-cut, 40-μm-thick, free-floating sections
were processed as above. For IHC, prior to adding the
primary antibody, control sections were incubated for
15 min in 3% hydrogen peroxide in PBS to quench
endogenous peroxidases and then washed. Quenching
had no effect on the staining outcome, so it was elimi-
nated in remaining experiments. The step was omitted
in the IC procedure because control experiments (incu-
bating fixed cells in the Vectastain color reaction
reagents) indicated that quenching did not affect the
color reaction.
Results
Western blot tests of p65 antibodies in WT and KO tissue
homogenates
There were several p65 antibodies that marked a single
protein migrating in the gel at the correct molecular
weight, and this marked band was absent in lanes con-
taining protein from p65 KO tissue. These were Santa
Cruz sc-372, NIH p65, and Invitrogen 2A12A7 monoclo-
nal (Figure 1a, 1b, 1d). Another set of p65 antibodies
marked proteins in multiple bands, including a band at
65 kDa that was absent in p65 KO tissue. These were
Epitomics 1546, (Figure 1c), CS 3034 (Figure 1e), CS
4764 (Figure 1f), sc-109 (Figure 1g), Calbiochem PC137
(Figure 1h), and the NCI repository antibodies 1226,
1774, 1207, and 33 (not shown). Finally there were sev-
eral antibodies that failed the KO test in that they marked
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proteins near the p65 molecular weight equally strongly
in from WT and KO tissues. These were MAB3026, sc-
8008, and CS 3037 (phospho-Ser276-p65) (Figure 2a-c).
The data for sc-8008 are enigmatic because the antibody
labeled a single band at the correct molecular weight
only in WT protein when applied to neurons in culture
but marked a similarly sized band from p65 KO protein
when applied to tissues, suggesting that it recognizes a
foreign protein that is not present in neurons. The blot
for 3037 was done on nuclear and cytosolic extracts from
cultured neurons that were unstimulated or glutamate
stimulated (100 μM for 10 min). Glutamate was tested
because of previous findings that glutamate is a stimulus
for NF-B activation in neurons [3].
The failure of the MAB3026 antibody was quite sur-
prising, given that in early publications, then named a-
p65M, it passed stringent tests for validity in cells trans-
fected with a construct overexpressing p65 [10]. There-
fore, we compared it closely with sc-372, which met the
criteria for specificity in the p65 KO test. In one set of
gels, neuronal proteins from p65 WT and KO were first
probed with MAB3026, and then the same blot was
stripped and re-probed with sc-372 (as well as GAPDH
to assess the protein loaded). To a second set, the oppo-
site was done; they were first probed with SC372 (Figure
2d), stripped and re-probed with MAB3026 (figure 2e)
(as well as GAPDH to assess the protein load). The gel
was then treated with both antibodies (Figure 2f). The
results clearly show that MAB3026 marks a protein
band that is different from the band marked by sc-372,
both in its location and its presence in KO tissue. In a
second test, a dual blot was made applying both
Figure 1 Western blots show p65 antibodies that passed the test of specificity in p65 KO tissues. Amounts of cell extract loaded per lane
indicated after each antibody. a, sc-372R (brain 20 μg, spleen 20 μg, liver 20 μg); b, NIH p65 (brain 40 μg, spleen 20 μg, liver 20 μg); c, Epitomics
1546 (brain 20 μg, spleen 20 μg); d, Invitrogen 2A12A7 (neurons 10 μg); e, Cell Signaling 3034 (brain 20 μg, spleen 40 μg); f, Cell Signaling 4764
(brain 40 μg, spleen 40 μg, liver 40 μg); g, Santa Cruz sc-109 (brain 40 μg, spleen 40 μg, liver 40 μg); h, Calbiochem PC137 (brain 20 μg). The
pattern of bands seen in h was identical to the patterns produced by the same antibody sold by Chemicon (AB 1604) and Rockland (100-4165)
(not shown). Arrows point to locations in blots of the protein identified as p65. WT, wildtype; KO, knockout tissue.
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MAB3026 and sc-372 primary antibodies at the same
time, with tubulin-bIII as the load protein marker (Fig-
ure 2g); the same result was obtained. Both experiments
clearly show differences in molecular weights of the pro-
teins being detected by the two antibodies in the blots
as well as the inability of MAB3026 to discriminate
between WT and p65 KO tissue samples.
Western blot tests of p50 antibodies in WT and KO tissue
homogenates
The Epitomics 1559 rabbit monoclonal antibody marked
a band at the correct molecular weight that was absent
in p50 KO tissues (Figure 3a). As expected, it also
marked a band at the molecular weight of p105, the pre-
cursor protein transcribed by the nfkb1 gene. Other p50
antibodies labeled multiple bands including a band at 50
kDa MW that was absent in p50 KO tissue. These
included Abcam 7971 (Figure 3b) and the NCI reposi-
tory antibodies 1157, 1263, and 1613 (not shown).
Finally, p50 antibodies that failed the specificity test
because they marked multiple bands and did not mark a
band at 50 kDa that was absent in p50 KO tissue
included sc-114 (Figure 3c), sc-8414 (Figure 3d), and
Upstate 06-886 (not shown).
Phospho-ser276-p65 antibodies
There are two sites of p65 phosphorylation, on serine
276 and serine 536 [1]. The mitogen and stress-activated
kinase-1 (MSK-1) and protein kinase A catalytic subunit
(PKAc) pathways lead to ser276 phosphorylation result-
ing in further NF-B activation [11-13]. The phospho-
ser276 form of p65 is reported to reside exclusively in
the cell nucleus [13]. In western blots, protein bands
stained by the Cell Signaling 3037 antibody raised
against phospho-ser276-p65 were confined to the
nucleus, as expected (Figure 4a). However, the stained
bands were not found at the expected position of p65 in
the gel, rather, they appeared at a lower and several
higher molecular weights. These upper bands were not
protein complexes containing p65 because the proteins
were thoroughly denatured before running on the gel.
The material was also treated with phosphatase
Figure 2 Western blots show p65 antibodies that failed the test of specificity in p65 KO tissues. a. The sc-8008 antibody showed staining
at approximately the correct molecular weight, but it was present also in p65 KO tissues. Curiously, in protein from cultured neurons, the protein
from KO cells was lacking. Protein load was 40 μg for brain, spleen and liver and 10 μg for neurons for both a and b. b. The MAB3026
monoclonal antibody against the p65 NLS showed a single band that was present in both WT and KO tissue. c. The CS 3037 antibody is raised
against the phosphorylated (at Ser276) form of p65. The staining was almost entirely in the nuclear (N) fraction, absent in the cytosolic (C)
fraction, and was induced in the high molecular weight range by glutamate (Glut) treatment (100 μM, 10 min) relative to unstimulated control
(Cont). However, the bands were not present at the expected molecular weight for phospho-p65. Protein (5 μg per lane) is from cortical
neurons. In d-g, proteins from cultured neurons were run to compare sc-372 and MAB3026. Compared with the band stained with sc-372 (d),
the band stained with MAB3026 runs in the gel at a slightly higher molecular weight (e). The same gel was probed for MAB3026 (e), then
stripped and re-probed for both antibodies simultaneously (f), or probed initially with both antibodies (g) to show that the single band marked
by the MAB3026 antibody is not the p65 epitope.
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inhibitors, precluding degradation of the protein. A
thorough proof of the failure of this and three other
commercial phospho-ser276-p65 antibodies to recognize
phosphorylated p65 in western blots of proteins from
cell lines has been published [14]. Interestingly, stimula-
tion of neuronal cultures with glutamate resulted in
increased staining of the large molecular weight bands
(Figure 4a). The bands could be induced also by treat-
ment with phorbol 12-myristate 13-acetate (PMA) or
forskolin (Figure 4b). Finally, the staining of multiple
bands was prevented if the tissues were treated with the
peptide against which the antibody was directed (Figure
4b). Similar results were obtained for Abcam’s ab2615
antibody directed against a similar region of phospho-
ser276-p65 (Figure 4c.). This antibody stained multiple
bands, none of which were at the correct molecular
weight for phosphorylated p65.
Similar results were obtained in IHC studies. Staining
was induced by KA in hippocampus (Figure 4e); it
Figure 3 Western blots show p50 antibodies that passed
(upper) and failed (lower) the test of specificity in p50 KO
tissues. The protein load was 20 μg per well in a and 50 μg in b, c,
and d. Arrows point to approximate 50 kDa MW or to 105 kDa as
indicated in the upper blots.
Figure 4 Western blots and immunohistochemistry show
nonspecific protein marking by antibodies raised against
phospho-ser276-p65. Antibody CS 3037 marking of proteins in
gels run with extracts from hippocampal neurons in culture was
exclusively nuclear, induced by 10 μM glutamate (a) or by 10 and
20 μM PMA or 20 or 30 μM forskolin (b) for 10 min. Marking of the
nuclear proteins was blocked by the synthetic peptide used for
immunization (2.5 μg per reaction in western blots) (c, d). However,
the induced labeled proteins did not migrate at the molecular
weight for p65. Immunohistochemical staining of the large
molecular weight proteins (but not phospho-ser276-p65) marked by
the phospho-ser276 antibody CS 3037 applied at 1:200 dilution is
shown in e-g. Intrahippocampal KA injection caused a rapid (within
15 min) local neuronal response in granule cell and pyramidal
neurons ipsilaterally (e, g) but not contralaterally (f, g). High-
magnification views of the dentate gyrus on the left (g) and right
(h) sides are taken from the boxed areas above. Preincubating the
tissue with 1 μl/ml of a 1 mg/ml phosphorylated (j) or non-
phosphorylated (i) p65 peptide fragment against which the
antibody was generated demonstrated that only the
phosphorylated peptide blocked the staining. Magnification bar in e
= 200 μm for d,e,h, i. Bar in g = 20 μm for f, g.
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appeared rapidly in neuronal nuclei (Figure 4g), and it
was blocked by the phosphorylated peptide against
which the antibody was raised (Figure 4j) but not by the
unphosphorylated form of the same peptide (figure 4i)
that was used to generate antibody 3034 sold by Cell
Signaling. The blocking was completely effective in
immunohistochemical studies of both tissues (Figure 4i
and 4j) and cells (not shown).
Use of the sc-372 p65 antibody for immunocytochemistry
and immunohistochemistry
Primary hippocampal or cortical neurons grown in low
density on coverslips were processed with the sc-372
p65 antibody for immunocytochemistry. In untreated
cells from WT mice, brown reaction product filled the
cell cytoplasm, including the larger processes (Figure
5a). The same pattern of staining was seen in cells from
p65 KO mice (Figure 5b). In another set of experiments,
cells grown on coverslips were processed for immuno-
fluorescence. For all antibodies tested–sc-372, NIH p65,
Epitomics 1546, CS 3034, and CS 4764–at a range of
dilutions–1:200 to 1:20,000–staining was seen in the
processes, cytoplasm, and nucleus of all cells, and no
consistent differences were seen for staining patterns in
either pure neurons (Figure 5) or mixed cells cultured
from WT or p65 KO fetal brains (data not shown).
Microtome-cut free-floating sections from perfusion-
fixed adult brain sections were also processed for immu-
nohistochemistry (Figure 6). The two antibodies that
showed high specificity in the western blot test, sc-372
and NIH p65, were applied to brain sections from ani-
mals that had been given KA to induce excitotoxicity in
the hippocampus. Survival times in these experiments
ranged from 15 min to 14 days. KA-induced effects
were observed in tissues at the three- and four-day sur-
vival times, reminiscent of published data using the sc-
372 antibody after similar kinds of treatments [15]. The
altered staining consisted of moderate elevations in
intensity in vascular endothelia and glial cells in the
region of injury (Figure 6a, 6c) contrasted with either
saline-injected control (Figure 6b) after i.v. injection or
the side opposite the intrahippocampal KA injection
(Figure 6d). The morphology of the glial cells most
resembled astrocytes (inset, Figure 6c). Staining filled
the cells, indicating both cytoplasmic and nuclear locali-
zation. Neurons showed no increased immunostaining.
Discussion
Cellular localization of p65 immunostaining in brain
Of the tested p65 antibodies, the polyclonal Santa Cruz
sc-372 antibody showed the strongest, most repeatable
pattern in western blots. In most blots, a single band
appeared in the location marked by the 70-kDa lane
marker. The single band was completely absent in the
RelA knockout (p65 KO) tissue, in brain, liver, and
spleen samples. A similar pattern was found with the
NIH p65 antibody. The four antibodies that met this
rigorous test of specificity were all raised against a por-
tion of the C-terminus of p65, which includes its trans-
activation domain (TAD). In contrast, antibodies raised
against the N-terminus or against the NLS region did
not meet the criteria for specificity. Thus, it is apparent
that the C-terminus contains antigenic peptide
sequences that are unique to p65, whereas other regions
of the molecule are not so selectively and strongly anti-
genic. The NLS region should be notably difficult to
raise selective antibodies against because the aa
sequences are conserved for a number of proteins that
have NLSs. The N-terminal Rel homology domain
(RHD) is conserved across other proteins, so this too
may not be a suitable region for antibodies. Finally, not
surprisingly, the rabbit monoclonal antibodies gave
excellent results. They are new and have not been used
in many publications to date.
Figure 5 Staining appearance is similar in cultured hippocampal neurons immunostained with the sc-372 antibody against p65. a.
neurons from WT mice. b. neurons from p65 KO mice. Primary antibody dilution was 1:700. Bar = 20 μm.
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The sc-372 antibody has been used in several publica-
tions to characterize NF-B activity in the brain. A
study by [15] examined the effects of intracerebroventri-
cularly injected KA-induced NF-B activity in the hip-
pocampus. This study is one of few to show a western
blot. The illustrated molecular weight range was con-
fined to 51-80 kDa, and in that range was a single band.
Intensity of the band increased in tissues from animals
surviving from 1 to 7 days. Immunohistochemistry of
the CA3 region of the hippocampus revealed induction
of staining in glial cells with the appearance of astro-
cytes or microglia (co-labeling with both cell types was
confirmed by double immunostaining with GFAP and
CD11b, respectively), and the staining was found in
both the nucleus and cytoplasm. This pattern of staining
was closely mimicked by the staining with the NIH p65
antibody (Figure 6c-e). It also agrees with the astrocyte-
like cellular staining in hippocampus 4 days after KA
injury in another study using the sc-109 antibody [16],
which we find to authentically mark p65 but also addi-
tional proteins in the western blot.
In human brain infarctions, a selective staining of glial
cells was seen by Terai [17] using the sc-372 antibody.
In the infarct area, microglial cells and blood vessels
were also stained. The entire cytoplasm of the cell
appeared stained, and such staining was largely absent
outside the infarct area.
In a study of status epilepticus seizures, which are
associated with neuronal loss, p65 staining with sc-372
was induced in astrocytes and blood vessels mainly in
the hippocampus and entorhinal cortex [18]. Constitu-
tive staining was minimal. There was no overlap of p65
staining and fluorojade staining of degenerating neurons.
Following immune challenge by i.p. IL-1b injection,
Nadjar et al. used the sc-372 antibody for IHC in rats
and mice to examine the cellular CNS response [19].
Background staining was low, and induction of staining
was seen in non-neuronal cells of the choroid plexus,
Figure 6 Immunohistochemical staining with sc-372 and NIH p65 antibodies in hippocampus after kainic acid (KA) treatment. In a and
b, KA (a) or saline (b) was injected i.v. three days previously. In c-e, KA was injected into the left CA3 four days previously. The CA3 label is
placed over the pyramidal cell layer in a-d. WM is the subcortical white matter. The inset shows darkly stained cells that appear to be astrocytes
or microglia in c, based on morphology and size. Neurons are unstained or very lightly stained in all panels. Blood vessels are moderately
stained in some sections, notably in a and b. Magnification bars in a and c = 100 μm for a,b and c,d. Bar in inset = 20 μm.
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circumventricular organs, and blood vessels. Co-localiza-
tion with astrocytes was positive. The temporal course
of activation, peaking in the 1-2 hour range, was mir-
rored also by IBa mRNA analyzed by RT-PCR. The
localization, cell type, and timing of this response was
rather perfectly matched by studies of IBa mRNA
induction visualized by ISHH after peripheral injections
of lipopolysaccharide [20] or IL-1b [21]. IBa is one of
the family of inhibitory proteins that hold NF-B in the
cytoplasm until it is activated [1]. Activation results in
degradation of IBa, which is followed typically by
increased transcription and synthesis of IBa to replace
the reserve of inhibitory molecules. Thus, IBa mRNA
induction is a reliable marker of NF-B activity in cells
[20]. Significantly, no published ISHH study has shown
neuronal induction of IBa mRNA in any model of
brain injury or other form of CNS activation.
Other IHC publications are more difficult to interpret.
Quite a few studies do not provide sufficient informa-
tion in the Method section to allow determination of
which specific antibody was used. A study by Gabriel
[22] does not specify which Santa Cruz rabbit polyclonal
p65 antibody was used (sc-109 or sc-372), but a western
blot showed a single band, suggesting it was sc-372.
Dilution of primary antibody was 1:1,000. In the study,
control cortex showed staining of the cell cytoplasm in
neurons, astrocytes and microglia. After an infarct,
endothelium and glial cells were strongly stained in the
ischemic area. Nuclear staining was predominant in
astrocytes, microglia, and macrophages. In a different
study of cortical injury using the sc-109 antibody for
IHC, combinations of neuronal and non-neuronal cells
were positively stained in the region of injury [23]. Simi-
larly with this antibody, a diffuse neuronal staining pat-
tern was replaced by a more specific staining of
astrocytes and microglia in the region of a cortical
injury induced by local injection of NMDA [24,25]. A
study of ischemia in the gerbil showed exclusively glial
(astrocytes and microglia) p65 staining in the hippocam-
pus with the monoclonal antibody (sc-8008) from Santa
Cruz [26]. This antibody showed specificity in cultured
neurons in the KO test (figure 2a). Results must be
interpreted with caution in work using p65 antibodies
that detected a band at the correct molecular weight in
WT but not KO tissues, but also marked bands at other
mobilities; these other proteins might be stained in IHC
material.
In summary, studies employing the antibody we have
characterized here as the best one for localizing authen-
tic p65 in brain have fairly consistently shown that p65
staining is not appreciably present in neurons and is not
induced in neurons after various brain insults. Rather,
p65 immunostaining is increased in endothelia, astro-
cytes, and microglia in these studies.
In contrast to the above summary, another group of
studies shows predominantly neuronal p65 staining,
both constitutively and after pathological insults. The
most widely used antibody for IHC to depict this pat-
tern of NF-B activity in the brain is the MAB3026 anti-
body against “activated” p65. The original p65 antibody
raised against the NLS region was a rabbit polyclonal
made by P. A. Baeuerle [27] and named a-p65NLS.
Later, an affinity purified monoclonal antibody of the
IgG3 isotype, called a-p65M [28] and a-p65Mab [29],
was used by the Kaltschmidts in early publications and
then distributed (as clone 12H11) by Boehringer-Man-
nheim (1697 838), Roche (1697838), and finally licensed
by Chemicon (Millipore) and sold as MAB3026. It was
made against the human p65 sequence
CDTDDRHRIEEKRKRT (NLS underlined). The authen-
ticity of the monoclonal antibody was determined by
western blot [10]. Interestingly, in normal 293 cells, a
single band appeared at around 67 kDa, but in 293 cells
with elevated p65 levels due to transfection with a
CMV-p65 plasmid construct, a dense band appeared at
67 kDa and a lighter band appeared just below it, at
around 65 kDa. Similar multiple banding patterns were
seen in western blots in a subsequent publication [30].
In light of the present western blot data showing that
the band marked by MAB3026 runs just above the band
marked by sc-372, it is possible that the faint lower
band is the authentic p65, and the major upper band is
an unknown protein with biological properties very
similar to p65.
In the early years, the MAB3026 antibody was used to
support the argument that there was constitutive and
induced NF-B activity in neurons [28,31]. Very high
concentrations of the antibody were typically used–in
the 1:30 to 1:150 dilution range. With this antibody,
injury-induced neuronal staining was shown in cerebral
cortex and the hippocampal CA fields at 1-3 days after
middle cerebral artery occlusion [32] or 1-2 days after
traumatic brain injury (TBI) [33] and in the hippocam-
pal CA fields 1 day after preconditioning by transient
ischemia or KA administration [34]. In human brain,
the MAB3026 antibody strongly stained cortical neurons
in the ischemic area following a stroke [35]. These data
are very different than the published data in similar
models described above that used the sc-372, sc-109,
and sc-8008 antibodies.
Following peripheral lipopolysaccharide (LPS) admin-
istration eliciting an inflammatory response in the brain,
ISHH showed strongly induced IBa mRNA expression
in non-neuronal cells of the meninges, blood vessels,
brain parenchyma, and circumventricular organs [20,21].
In striking contrast, in this same LPS administration
paradigm, IHC of p65 staining using MAB3026 showed
exclusively neuronal induction in one brain region
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adjacent to one circumventricular organ [36]. It is not
known what factors would produce this pattern of
staining.
Cellular localization of p50 immunostaining in brain
Of the tested p50 antibodies, the Epitomics 1559 rabbit
monoclonal antibody raised against a peptide sequence
located between aas 340 and 370 of p50 was the best
antibody in the study. It is new and has not been used
in published studies of brain localization or activity. In
contrast, the Santa Cruz sc-114 antibody, raised against
the NLS region at aas 357-365 to generate an “activated
p50” antibody, was clearly not directed against p50 in
our gels. This fact has already been published [37]. In
that study, thymic whole cell extracts from WT and p50
KO mice were used to show that the sc-114 antibody
produced several nonspecific bands of incorrect molecu-
lar weight that appeared identically in both WT and p50
KO tissues run on western blots. Despite the early
knowledge that sc-114 did not recognize p50, several
publications have used it to show neuronal p50 localiza-
tion in hippocampal CA cells following KA- or NMDA-
induced damage [38-41]. These results are counter to
the outcomes, described above, using the sc-372 anti-
body against p65.
The cautionary story of antibodies to phospho-ser276-
p65
A study has already been published showing the lack of
specificity of this and other phospho-ser276-p65 antibo-
dies in a number of cell lines [14]. Our findings extend
the list of targets, namely primary neurons and brain
cells, against which the 3037 antibody does not recognize
Ser276-phosphorylated p65. Staining was completely
blocked by the phosphorylated peptide against which the
antibody was raised. Peptide blocking is a standard test
for peptide specificity, but it only shows that the antibody
is specific for the peptide it was raised against and not
the native protein containing the peptide sequence. The
case of a single band migrating on a western blot at the
appropriate molecular size being effectively competed
away by the blocking peptide can be viewed as an ade-
quate test of the specificity of the antibody. However,
when multiple bands of inappropriate molecular size are
present on the western blot and they are all competed
away by the blocking peptide, a question of the specificity
of this antibody is raised as it appears that the antibody is
recognizing nonspecific epitopes in unrelated proteins.
Thus, while passing this traditional test of specificity,
3037 failed to mark a protein in the gels at the correct
molecular weight (at around 65-70 kDa in our gels) that
was also absent in the p65 KO mouse.
The amino acids surrounding ser276 of p65 contain
sequences that are also found in proteins that are
phosphorylated by a number of enzymes, so it is possi-
ble that the antibody marked unknown phosphorylated
proteins of large molecular weight. Indeed, these pro-
teins were very responsive to glutamate treatment as
indicated in western blots by intensified bands of
nuclear but not cytoplasmic proteins appearing within
minutes of glutamate stimulation, in immunohisto-
chemically stained hippocampal neurons following in
vivo KA treatments (Figure 4), and in nuclei of hippo-
campal neurons in culture after glutamate treatment
(not shown). Glutamate acts through Ca++ and enzymes
like PKC and PKA to phosphorylate nuclear proteins. In
one study, glutamate stimulated the production of PKC-
phosphorylated proteins at 48, 87, and 120 KDa molecu-
lar weight in hippocampal neurons [42]. We found that
the bands at around 90 and 130 kDa were dose-depen-
dently increased in intensity by treatment with PMA
(which activates PKC) and with forskolin (which acti-
vates PKA). Further work is needed to identify the
actual targets of the 3037 antibody.
Neuronal immunostaining with p65 and p50 antibodies
We show here that even antibodies that pass the test of
specificity on western blots still label cells nonspecifi-
cally when used for IHC. The probable reason for this is
that the levels of p50 and p65 in neurons are so low
that they cannot be detected by this method. Raising the
concentration of the primary antibody to the point that
cellular staining becomes visible amounts to nonspecific
staining, which we see even at 1:500 dilution of authen-
ticated antibodies. Antibodies that mark additional pro-
teins in the western blots are even more difficult to
interpret when used for IHC, especially in reports of
changes in staining levels induced by various manipula-
tions. It is unlikely that the changes measured are due
to alterations in levels of p65 or p50. Any of the other
proteins recognized by these antibodies might contribute
to the immunohistochemical outcome. We (Listwak et
al., unpublished data) and others [43] have found that
NF-B in neurons is rather unresponsive to stimulatory
challenges of all kinds. Consequently, recent reports of
altered NF-B activity inferred from changes in subunit
immunostaining following mild challenges like electrical
stimulation of afferent pathways [44], passive avoidance
learning [45], or psychological stress [46] need to be
viewed with great skepticism. These finding are further
rendered suspect by the use of the MAB3026 antibody
[44,45,47], the use of unidentified Santa Cruz p65, p50,
and IBa antibodies without designation of catalog
numbers [46], and by the fact that the brain focus of the
studies is the hippocampus, which has layers of very
tightly packed neurons that render the appearance of
specific staining, especially at low magnification, because
of the high neuronal packing density. With antibodies
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such as sc-372 and NIH p65, we find that neurons are
the least stained and most unresponsive of all the cellu-
lar phenotypes in the hippocampus but are visible
because of the high packing density (note CA3 cell layer
in Figure 6b, 6d).
The close functional association of p50 with p65
should result in similar immunohistochemical staining
patterns in tissues following manipulations. A few stu-
dies have used p50 antibodies other than sc-114 for IHC
in brain. Some used antibodies distributed by Warner
Greene (Gladstone Institute). A p50 antibody named Ab
392 raised against the N-terminus was used in several
IHC publications following its characterization in COS
cells [48]. A western blot of brain extracts showed a
band at 50 kDa plus multiple additional bands [49].
Dying hippocampal neurons were immunostained in
that study and in a similar study that also used an N-
terminus-directed p65 antibody from Greene called Ab
567 [50]. In another study by the same group, after cere-
bral infarct, both p50 and p65 antibodies from Greene
stained neurons of all types in the infarct area with little
staining outside the infarct area [51]. Neuronal staining
with the p50 Ab 392 antibody appeared in one study in
which every neuron of the medial septum was immu-
nostained in the normal young brain, and the staining
did not change following deafferentation by fornix trans-
ection [52]. It is difficult to assess the significance of
these studies without knowing whether or not the anti-
bodies were really specific for p50. Further work with
authenticated p50 monoclonal antibodies is warranted.
A p50 antibody made by Mariagrazia Grilli (CNR Insti-
tute of Neuroscience, Milan, Italy) but not commercially
available passed the test of marking single bands at 50
and 105 kDa in a western blot that were absent in p50
KO tissue, and it was used to show staining of radial glial
cells in the subventricular zone and in the rostral migra-
tory stream [53]. The authors did not show absence of
such immunostaining in p50 KO tissue, however.
Summary and conclusions
Widely used antibodies raised against the NF-B subu-
nits p65 and p50 were subjected to the test of specificity
in WT and KO tissues, and several of the antibodies
that failed the test of specificity are the ones that have
been used in published studies to argue for neuronal
activation of NF-B in the brain following neurotoxic or
other challenges. Antibodies that rigorously passed the
specificity test show little specific neuronal immunos-
taining either in cell culture or brain, whereas they do
mark non-neuronal cells in brains subjected to toxic or
excitatory challenges. The data help to explain confusion
in the literature about the role of NF-B in neuronal
function and injury. The lack of neuronal NF-B
response observed with the authentic p65 antibodies is a
finding consistent with studies employing in situ hybri-
dization histochemistry showing non-neuronal localiza-
tion of induced IBa mRNA expression in injury,
infection, and pain models [20,54-56] and of known NF-
B-regulated genes in similar models [57-61]. Future
studies with validated monoclonal antibodies and mole-
cular tools such as a knock-in p65-GFP fusion protein
[62] (but note the caveats associated with this approach
[63]) will provide the proper means to address the cellu-
lar localization of NF-B activation in the brain.
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